Researchers at UC San Francisco have recently discovered genetic mutations in a protective protein called Capicua (CIC). The scientists demonstrated that there is a disproportionate frequency of mutated CIC in human lung cancers that have metastasized.
Researchers from Moffitt Cancer Center’s Integrated Mathematical Oncology (IMO) Department are overcoming some of the limitations of common preclinical experiments and clinical trials by studying cancer through mathematical modeling.
The US Food and Drug Administration (FDA) in record time has approved nivolumab (Opdivo) for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after a platinum-based therapy.
Medical researchers at Indiana University Bloomington are reporting that prostate cancer may be much more closely related to Ewing’s sarcoma than previously recognized.
Researchers discover that CCL3-receptor antagonists could help control the development of leukemia in patients with Noonan syndrome
Two new studies are suggesting that PIM1 inhibitors, which are already in clinical trials for leukemia and multiple myeloma (MM), may help combat triple-negative breast cancer.
A new collaboration among industry, nonprofit, academia, and the federal government may lead to a change in the treatment paradigm for acute myeloid leukemia.
New immunotherapies that target PD-1 are now showing promise for first-line and second-line treatment of metastatic bladder cancer.
An experimental checkpoint inhibitor called avelumab may produce quick and durable responses in some patients with metastatic Merkel cell carcinoma.
A new study is suggesting that radiomic features subjected to machine learning algorithms may be able to identify imaging signatures that defined a subset of patients with recurrent glioblastoma who may gain the most benefit from antiangiogenic therapy.